ESR1 and breast carcinoma: Accordingly, inhibition of the MAPK pathway leading to inactivation of myogenin or Myc could lead to down-regulation of ATAD3B and thus provide a putative therapeutic target for post-menopausal ER+/HER2− breast cancer patients.